Real-Life Clinical Efficacy of Acoramidis in Participants With ATTR-CM and Association With Cardiac Biomarkers

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

PHASE4

Total Enrollment

200 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-10-01

Study Completion Date

2028-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to confirm that the treatment with acoramidis prevents the deterioration of the ATTR-CM disease progression index and that these indexes are surrogate markers of disease progression.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

ATTR-CM: A Multi-country, Non-interventional Disease Registry

NCT06651073

Transthyretin Amyloid Cardiopathy

RECRUITING

Implementation of Standardized Early Identification and Diagnosis for Transthyretin Amyloidosis (ATTR) in High-Risk Populations

NCT07338942

ATTR-CM

NOT_YET_RECRUITING NA

Clinical Study of ATTR-CM

NCT04935021

Transthyroxine Amyloidosis Cardiomyopathy

RECRUITING PHASE4

ATTR Amyloid Cardiomyopathy: Characterization of Extracellular Vesicles as Potential Disease Stratifiers and Prognostic Biomarkers

NCT07314268

Wild-type ATTR Amyloidosis Amyloidosis Cardiac Amyloidosis, Hereditary +1 more

RECRUITING

Multimodality Cardiac Imaging for Disease Progression in ATTR-CM

NCT07112066

Amyloidosis Cardiac

RECRUITING NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Transthyretin-type Cardiac Amyloidosis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Acoramidis

Participants will receive 800 mg of acoramidis twice daily for 18 months.

Group Type EXPERIMENTAL

Acoramidis

Intervention Type DRUG

Participants will receive acoramidis tablets orally.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Acoramidis

Participants will receive acoramidis tablets orally.

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

acoramidis hydrochloride Byontra

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Treatment history of ATTR-CM is one of the following:
* Naive participants: newly diagnosed with ATTR-CM and no prior treatment with drugs for ATTR-CM
* Switch participants: Participants who are using tafamidis, a TTR stabilizer, as treatment for ATTR-CM and who, in the judgment of the post-marketing clinical trial investigator (co-principal investigator), can be expected to benefit from switching to acoramidis.
* Naive participants must meet the following requirements:

1. History of hospitalization for heart failure or heart failure symptoms requiring treatment, including diuretics
2. Echocardiographic end-diastolic ventricular septal thickness greater than 12 millimeters (mm)
3. Confirmed diagnosis of ATTR-CM (wild type or mutant) by one of the following diagnostic methods

1. Tissue biopsy shows amyloid deposition and TTR precursor protein is identified by immunohistochemistry or mass spectrometry.
2. Bone scintigraphy showing strong accumulation \*\* (Perugini score ≥ 2) consistent with myocardium and no M protein, negating the possibility of AL amyloidosis

Exclusion Criteria

* Have confirmed diagnosis of AL amyloidosis
* Switch participants: prior treatment with gene silencing agents (pachysilane sodium, butrisilane sodium) as treatment for ATTR-CM (including when specifically scheduled to start treatment with a gene silencing agent)
* Likelihood of receiving a heart transplant within 1 year from the time screening begins
* Hypersensitivity to acoramidis, its metabolites, or additives in the formulation has been confirmed.
* Pregnant or lactating women
* Has a clinically significant medical condition, an abnormal laboratory test result, or a condition that may jeopardize the safety of the study participant, increase the risk of participation in the post-marketing clinical trial, or affect the study
* Participating in an interventional study other than this study, including a clinical trial
* In the opinion of the responsible (sub)physician for the post-marketing clinical trial, has a history of drug abuse, alcoholism, or psychiatric disorder that would preclude compliance with this Post-Marketing Clinical Study Protocol

Minimum Eligible Age

18 Years

Maximum Eligible Age

100 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.